Clinical trials: Relapsed
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
Off-the-shelf CD123 CAR-NK for R/R AML
This is a single-centre, single-arm, open-label, first-in-human (FIH) study to evaluate the safety, tolerability and preliminary efficacy of universal Off-the-shelf CAR-NK cells targeted CD123 (JD123 injection) in the treatment…
- Trial name
- NCT06201247
- Testing
- JD123 injection
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Peking University People's Hospital
Lymphoma, Non-Hodgkin, Lymphoma, B-Cell
Study of CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell
This is a phase 1/1b, interventional single arm, open label, treatment study designed to evaluate the safety and feasibility of infusion of autologous T cells engineered to contain an anti-cluster of differentiation 19 (CD19) and…
- Conditions
- Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Trial name
- NCT03019055
- Testing
- CAR-20/19-T cells (1.0 x10^5 CAR-20/19-T cells/kg), CAR-20/19-T cells (2.5 x10^5 CAR-20/19-T cells/kg), CAR-20/19-T cells (7.5 x10^5 CAR-20/19-T cells/kg)
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Medical College of Wisconsin
Epstein Barr Virus Associated Non Hodgkin's Lymphoma, Epstein Barr Virus Associated Hodgkin's Lymphoma
Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma
By combining a variety of agents that potentiate Zidovudine (ZDV), the investigators hope to induce remission in this generally fatal disease.
- Conditions
- Epstein Barr Virus Associated Non Hodgkin's Lymphoma, Epstein Barr Virus Associated Hodgkin's Lymphoma, Post-Transplant Lymphoproliferative Disease
- Trial name
- NCT01964755
- Testing
- Doxorubicin, Methotrexate, Leucovorin
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- University of Miami
Gastrointestinal Stromal Tumor
Oblimersen and Imatinib Mesylate in Treating Patients With Advanced Gastrointestinal Stromal Tumors That Cannot Be Removed By Surgery
Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Oblimersen may help imatinib mesylate kill more tumor cells by making tumor cells more sensitive to the drug.
- Trial name
- NCT00091078
- Testing
- oblimersen sodium, imatinib mesylate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- National Cancer Institute (NCI)
Relapsed DLBCL and PT/NKCLs
Clinical Trial of Mitoxantrone HCL Liposome Injection in Patients With Relapsed DLBCL and PT/NKCLs
To study efficacy and safety of Mitoxantrone HCL Liposome Injection in patients with diffuse large B-cell lymphoma and lymphoma peripheral T cell.
- Trial name
- NCT02597387
- Testing
- Mitoxantrone HCL Liposome Injection
- Where
- China
- Volunteers
- 50 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Hodgkin Lymphoma
Immunological Senescence Phenotype as a Resistance Profile to Pembrolizumab in Patients With Relapsed/Refractory Hodgkin's Lymphoma
This is a single-centre, observational, prospective and exploratory study, which involves the use of human tissues from patients affected by Relapsed/Refractory classic Hodgkin Lymphoma treated with pembrolizumab at the…
- Trial name
- HL-SIP (NCT06733987)
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Refractory/Relapse Acute Myeloid Leukemia
Venetoclax Combined With Azacitidine and CAG in Refractory/Relapse Acute Myeloid Leukemia
This study aims to assess the therapeutic efficacy and safety of venetoclax in combination with azacitidine and CAG as induction regimen in Patients with Refreactory/Relapse Acute Myeloid Leukemia.
- Trial name
- NCT05807347
- Testing
- Venetoclax
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Hematology department of the 920th hospital
Relapsing Remitting Multiple Sclerosis
Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis (MS)CombiRx
This is for a randomized clinical trial (RCT) to determine if the combined use of interferon beta-1a (IFN) and glatiramer acetate (GA) is a measurably better therapy than either agent used individually in patients with…
- Trial name
- NCT00211887
- Testing
- Interferon beta 1-a, glatiramer acetate
- Where
- 71 sites in United States, Canada
- Volunteers
- 1,008 people
- Sponsor
- Fred Lublin
Refractory Multiple Myeloma, Relapsed Multiple Myeloma
Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma
The purpose if this study is to evaluate the side effects of the combination of bortezomib and Revlimid (CC-5013) in patients with relapsed and relapsed/refractory multiple myeloma.
- Conditions
- Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Multiple Myeloma
- Trial name
- NCT00153933
- Testing
- Bortezomib, CC-5013
- Where
- 6 sites in United States
- Volunteers
- 58 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Cancer
CYP2D6 Genotyping by AmpliChipTM CYP450 for Tamoxifen-Treated Breast Cancer Patients
The aim of the study is to examine whether tamoxifen-treated Israeli breast cancer patients who are CYP2D6 poor metabolizers (CYP2D6*4/*4 genotype) are at higher cancer relapse risk during 2.5-5-year follow-up period from initial…
- Trial name
- NCT00815555
- Testing
- There is no intervention - this is an observational study
- Where
- Israel
- Volunteers
- 500 people
- Sponsor
- Assaf-Harofeh Medical Center
Hematologic Malignancy
Composite Health Assessment Risk Model (CHARM) for Older Adults (BMT CTN 1704)
Prospective observational multicenter study of allogeneic Hematopoietic Stem Cell Transplantation (HCT) in recipients 60 years and older to assess important determinants of health status to be combined into a composite health…
- Trial name
- BMT CTN 1704 (NCT03992352)
- Testing
- Age 60+ with planned HCT for Hematologic Malignancy
- Where
- 50 sites in United States
- Volunteers
- 1,229 people
- Sponsor
- Center for International Blood and Marrow Transplant Research
Relapsing-Remitting Multiple Sclerosis, Urinary Incontinence
Guided Versus Non-guided Pelvic Floor Exercises for Urinary Incontinence in Relapsing-Remitting Multiple Sclerosis
The aim of the study is to evaluate the effectiveness of guided versus non guided pelvic floor exercises for urinary incontinence in patients with Relapsing-Remitting Multiple Sclerosis
- Trial name
- NCT03000647
- Testing
- Pelvic floor exercises guided by a physiotherapist, Non guided pelvic floor exercises
- Where
- Spain
- Volunteers
- 48 people
- Sponsor
- Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
Non-Hodgkin's Lymphoma
A Phase I Dose Escalation Study of RAD001 Administered in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
This study assesses the tolerability, safety, efficacy and pharmacokinetics of everolimus in Japanese patients. Everolimus is administered orally everyday to adult patients with relapsed or refractory non-Hodgkin's lymphoma who…
- Trial name
- NCT00622258
- Testing
- Everolmus
- Where
- 8 sites in Japan
- Volunteers
- 13 people
- Sponsor
- Novartis Pharmaceuticals
Relapsed or Refractory Acute Lymphoblastic Leukemia
A Phase I Study Evaluating Safety and Efficacy of C-CAR011 Treatment in Adult Subjects With r/r CD19+B-ALL
The trial is a single arm, single-center, non-randomized phase I clinical trial which is designed to evaluate the safety and efficacy of C-CAR011 in treatment of adult subjects with relapsed/refractory CD19+ B cells acute…
- Trial name
- NCT03018093
- Testing
- C-CAR-011
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai AbelZeta Ltd.
Non-Hodgkin's Lymphoma
Phase 1 Study of Radiosensitization Using Bortezomib in Relapsed Non-Hodgkin's Lymphoma Patients Receiving Radioimmunotherapy
This will be a multi-center, Phase I, dose-escalation study of bortezomib in combination with 131I-tositumomab in patients with relapsed non-Hodgkin's lymphoma.
- Trial name
- NCT00777114
- Testing
- bortezomib, tositumomab
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- Weill Medical College of Cornell University
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
This phase I trial studies the side effects and best dose of ruxolitinib when given together with venetoclax and compares the effect of ruxolitinib in combination with venetoclax to venetoclax and azacitidine in treating patients…
- Conditions
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Secondary Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
- Trial name
- NCT03874052
- Testing
- Azacitidine, Biospecimen Collection, Bone Marrow Aspiration
- Where
- 3 sites in United States
- Volunteers
- 51 people
- Sponsor
- Jennifer Saultz
Lymphoma, Large B-Cell, Diffuse, Transplantation
PD-1 Inhibitor Tislelizumab Maintenance Therapy in R/R DLBCL Patients After ASCT
This is a multicenter, randomized controlled, prospective clinical trial. The objective is to investigate the efficacy and safety of Tislelizumab maintenance therapy in newly diagnosed diffuse large B-cell lymphoma (DLBCL)…
- Conditions
- Lymphoma, Large B-Cell, Diffuse, Transplantation, Chemotherapy
- Trial name
- NCT04799314
- Testing
- PD-1 Inhibitor Tislelizumab maintenance therapy
- Where
- China
- Volunteers
- 132 people
- Sponsor
- Ruijin Hospital
Relapsed and Refractory Multiple Myeloma
Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma
Master protocol for cell therapy, Phase 1 proof-of-concept studies in relapsed and refractory multiple myeloma and includes long-term safety follow-up.
- Trial name
- NCT04155749
- Testing
- anitocabtagene-autoleucel
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Kite, A Gilead Company
Relapsed or Refractory Multiple Myeloma
Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel (Abraxane) in the Treatment of Relapsed/Refractory Multiple Myeloma
The investigators will perform a phase I/II trial of Revlimid daily for 21 days and Abraxane weekly for 3 weeks. Accrual will be on standard cohorts of 3 patients.
- Trial name
- rev/abraxane (NCT02075021)
- Testing
- Lenalidomide, nab-paclitaxel
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- NYU Langone Health
Multiple Myeloma
First in Human Dose Escalation of M3258 as a Single Agent and Expansion Study of M3258 in Combination With Dexamethasone
The purpose of this study was to determine the safety, tolerability, pharmacokinetics, pharmacodynamics and early efficacy signs of M3258 as a single agent and co-administered with dexamethasone in participants with Relapsed…
- Trial name
- NCT04075721
- Testing
- M3258, M3258 20 mg
- Where
- 7 sites in United States, France
- Volunteers
- 10 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.